| Issue Date |
Title |
Author(s) |
| Mar-2021 |
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial |
Zhou, Caicun;Chen, Gongyan;Huang, Yunchao;Zhou, Jianying;Lin, LiZhu;Feng, Jifeng;Wang, Zhehai;Shu, Yongqian;Shi, Jianhua;Hu, Yi;Wang, QiMing;Cheng, Ying;Wu, Fengying;Chen, Jianhua;Lin, Xiaoyan;Wang, Yongsheng;Huang, Jianan;Cui, Jiuwei;Cao, Lejie;Liu, Yunpeng;Zhang, Yiping;Pan, Yueyin;Zhao, Jun;Wang, LiPing;Chang, Jianhua;Chen, Qun;Ren, Xiubao;Zhang, Wei;Fan, Yun;He, Zhiyong;Fang, Jian;Gu, Kangsheng;Dong, XiaoRong;Zhang, Tao;Shi, Wei;Zou, Jianjun |
| Jul-2021 |
D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). |
Lu, Shun;Zhang, Yiping;Zhang, Guojun;Zhou, Jianying;Cang, Shundong;Cheng, Ying;Wu, Gang;Cao, Peiguo;Lv, Dongqing;Jin, Xiangming;Jian, Hong;Chen, Chengshui;Jiang, Guanming;Tian, Panwen;Wang, Kai;Zhao, Hui;Chen, Gongyan;Chen, Qun;Ding, Cuimin;Yang, Junquan;Guo, Renhua;Sun, Guoping;Wang, Bin;Jiang, Liyan;Zhuang, Wu;Liu, Zhe;Fang, Jian;Liu, Yunpeng;Zhang, Jian;Chen, Jun;Pan, Yueyin;Yu, Qitao;Zhao, Min;Cui, Jiuwei;Li, Dianming;Yi, Tienan;Yu, Zhuang;Yang, Yan;Zhang, Yan;Zhi, Xiuyi;Huang, Yunchao;Wu, Rong;Chen, Liangan;Zang, Aimin;Cao, Lejie;Li, Qingshan;Li, Xiaoling;Song, Yong;Wang, Donglin;Zhang, Shucai |
| Aug-2021 |
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study |
Ai, Xinghao;Pan, Yueyin;Shi, Jianhua;Yang, Nong;Liu, Chunling;Zhou, Jianying;Zhang, Xiaodong;Dong, Xiaorong;He, Jianxing;Li, Xiaoling;Chen, Gongyan;Li, Xingya;Zhang, Helong;Liao, Wangjun;Zhang, Yiping;Ma, Zhiyong;Jiang, Liyan;Cui, Jiuwei;Hu, Chunhong;Wang, Wei;Huang, Cheng;Zhao, Jun;Ding, Cuimin;Hu, Xiaohua;Wang, Kai;Gao, Beili;Song, Yong;Liu, Xiaoqing;Xiong, Jianping;Liu, Anwen;Li, Junling;Liu, Zhe;Li, Yinyin;Wang, Mengzhao;Zhang, Biao;Zhang, Dan;Lu, Shun |
| 1-Jan-2021 |
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study |
Zhang, Li;Meng, Li;Liu, Bingcheng;Zhang, Yanli;Zhu, Huanling;Cui, Jiuwei;Sun, Aining;Hu, Yu;Jin, Jie;Jiang, Hao;Zhang, Xi;Li, Yan;Liu, Li;Zhang, Wanggang;Liu, Xiaoli;Gu, Jian;Qiao, Jianhui;Ouyang, Guifang;Liu, Xin;Luo, Jianmin;Jiang, Ming;Xie, Xiaobao;Li, Jianyong;Zhao, Chunting;Zhang, Mei;Yang, Tonghua;Wang, Jianxiang |
| 2019 |
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study. |
Li, Zhang;Meng, Li;Zhang, Yanli;Zhu, Huanling;Cui, Jiuwei;Sun, Aining;Hu, Yu;Jin, Jie;Jiang, Hao;Zhang, Xi;Li, Yan;Liu, Qifa;Liu, Li;Zhang, Wanggang;Gu, Jian;Qiao, Jian-Hui;Liu, Bingcheng;Zhang, Fengkui;Guo, Yong;Wang, Jianxiang |
| 2012 |
Gaining a comprehensive understanding of pruritus |
Zhang, Haiiao;Yang, Yi;Cui, Jiuwei;Zhang, Yaqin |
| Nov-2022 |
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy |
Wu, Fengying;Jiang, Tao;Chen, Gongyan;Huang, Yunchao;Zhou, Jianying;Lin, Lizhu;Feng, Jifeng;Wang, Zhehai;Shu, Yongqian;Shi, Jianhua;Hu, Yi;Wang, Qiming;Cheng, Ying;Chen, Jianhua;Lin, Xiaoyan;Wang, Yongsheng;Huang, Jianan;Cui, Jiuwei;Cao, Lejie;Liu, Yunpeng;Zhang, Yiping;Pan, Yueyin;Zhao, Jun;Wang, LiPing;Chang, Jianhua;Chen, Qun;Ren, Xiubao;Zhang, Wei;Fan, Yun;He, Zhiyong;Fang, Jian;Gu, Kangsheng;Dong, Xiaorong;Zhang, Tao;Shi, Wei;Zou, Jianjun;Bai, Xuejuan;Ren, Shengxiang;Zhou, Caicun |
| Aug-2021 |
A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients (vol 147, pg 259, 2020) |
Wang, Zhijie;Zhao, Jun;Ma, Zhiyong;Cui, Jiuwei;Shu, Yongqian;Liu, Zhe;Cheng, Ying;Leaw, Shiang J.;Wu, Yanjie;Ma, Yan;Tan, Wei;Ma, Xiaopeng;Zhang, Yun;Wang, Jie |
| Sep-2022 |
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blin |
Lu, Shun;Wu, Lin;Jian, Hong;Chen, Ying;Wang, Qiming;Fang, Jian;Wang, Ziping;Hu, Yanping;Sun, Meili;Han, Liang;Miao, Liyun;Ding, Cuimin;Cui, Jiuwei;Li, Baolan;Pan, Yueyin;Li, Xingya;Ye, Feng;Liu, Anwen;Wang, Ke;Cang, Shundong;Zhou, Hui;Sun, Xing;Ferry, David;Lin, Yong;Wang, Shuyan;Zhang, Wen;Zhang, Chengli |
| Feb-2022 |
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial |
Zhou, Caicun;Wang, Ziping;Sun, Yuping;Cao, Lejie;Ma, Zhiyong;Wu, Rong;Yu, Yan;Yao, Wenxiu;Chang, Jianhua;Chen, Jianhua;Zhuang, Wu;Cui, Jiuwei;Chen, Xueqin;Lu, You;Shen, Hong;Wang, Jingru;Li, Peiqi;Qin, Mengmeng;Lu, Dongmei;Yang, Jason |
